A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects

INTRODUCTION: The aim of the study was to demonstrate the bioequivalence, and compare the safety and tolerability of MSB11022, a proposed biosimilar of adalimumab, when delivered by either an autoinjector (AI) or a pre-filled syringe (PFS). METHODS: In this pharmacokinetic (PK), parallel group, open...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabet, Ahad, Dickerson, Daniel S., Kunina, Eugenia E., Buccarello, Anna Lucia, Monnet, Joëlle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964896/
https://www.ncbi.nlm.nih.gov/pubmed/35262901
http://dx.doi.org/10.1007/s40744-022-00432-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964896/
https://www.ncbi.nlm.nih.gov/pubmed/35262901
http://dx.doi.org/10.1007/s40744-022-00432-1

Ejemplares similares